BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kocova M, Anastasovska V, Falhammar H. Clinical outcomes and characteristics of P30L mutations in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocrine 2020;69:262-77. [PMID: 32367336 DOI: 10.1007/s12020-020-02323-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Kocova M, Concolino P, Falhammar H. Characteristics of In2G Variant in Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency. Front Endocrinol 2022;12:788812. [DOI: 10.3389/fendo.2021.788812] [Reference Citation Analysis]
2 Espinosa Reyes TM, Collazo Mesa T, Lantigua Cruz PA, Agramonte Machado A, Domínguez Alonso E, Falhammar H. Genotype-Phenotype Correlation in Patients with Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency in Cuba. Int J Endocrinol 2021;2021:9316284. [PMID: 33505466 DOI: 10.1155/2021/9316284] [Reference Citation Analysis]
3 Kocova M, Anastasovska V, Petlichkovski A, Falhammar H. First insights into the genetics of 21-hydroxylase deficiency in the Roma population. Clin Endocrinol (Oxf) 2021;95:41-6. [PMID: 33605469 DOI: 10.1111/cen.14447] [Reference Citation Analysis]
4 Nordenström A, Lajic S, Falhammar H. Clinical outcomes in 21-hydroxylase deficiency. Curr Opin Endocrinol Diabetes Obes 2021;28:318-24. [PMID: 33741777 DOI: 10.1097/MED.0000000000000625] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Falhammar H, Frisén L, Hirschberg AL, Nordenskjöld A, Almqvist C, Nordenström A. Increased Prevalence of Fractures in Congenital Adrenal Hyperplasia: A Swedish Population-Based National Cohort Study. J Clin Endocrinol Metab 2021:dgab712. [PMID: 34601607 DOI: 10.1210/clinem/dgab712] [Reference Citation Analysis]